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Abstract
An update of the 2010 published ESUR recommendations of
MRI of the sonographically indeterminate adnexal mass inte-
grating functional techniques is provided. An algorithmic ap-
proach using sagittal T2 and a set of transaxial T1 and T2WI
allows categorization of adnexal masses in one of the follow-
ing three types according to its predominant signal character-
istics. T1 'bright' masses due to fat or blood content can be
simply and effectively determined using a combination of
T1W, T2W and FST1W imaging. When there is concern for
a solid component within such a mass, it requires additional
assessment as for a complex cystic or cystic-solid mass. For
low T2 solid adnexal masses, DWI is now recommended.
Such masses with low DWI signal on high b value image
(e.g. > b 1000 s/mm2) can be regarded as benign. Any other
solid adnexal mass, displaying intermediate or high DWI sig-
nal, requires further assessment by contrast-enhanced
(CE)T1W imaging, ideally with DCE MR, where a type 3
curve is highly predictive of malignancy. For complex cystic
or cystic-solid masses, both DWI and CET1W—preferably
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DCE MRI—is recommended. Characteristic enhancement
curves of solid components can discriminate between lesions
that are highly likely malignant and highly likely benign.
Key Points
• MRI is a useful complementary imaging technique for
assessing sonographically indeterminate masses.
• Categorization allows confident diagnosis in the majority of
adnexal masses.
• Type 3 contrast enhancement curve is a strong indicator of
malignancy.
• In sonographically indeterminate masses, complementary
MRI assists in triaging patient management.
Keywords Magnetic resonance imaging .Ovarianneoplasm .
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Introduction
The previous guidel ines for MR imaging of the
sonographically indeterminate adnexal mass suggested a basic
examination involving T1-weighted imaging (T1WI) and T2-
weighted imaging (T2WI) to determine the nature and key
signal characteristics of the mass, supplemented by additional
oblique T2W imaging, fat-suppressed T1W (FST1W) or
contrast-enhanced T1W (CET1W) imaging, depending on
the key characteristic of the mass [1].
Recently, much effort has been invested in improving pre-
surgical diagnosis of adnexal tumours by developing risk
models and scoring systems using sonography [2–4]. In clin-
ical routine, 5–25 % of adnexal lesions will remain indetermi-
nate after sonography [2]. Even using the International
Ovarian Tumour Analysis group (IOTA) simple rules, 22 %
of lesions remained indeterminate on ultrasound (US) [4].
Most of these turn out to be common benign entities such as
haemorrhagic lesions, fat-poor mature teratomas, uterine
leiomyomas and ovarian fibromas [5]. The clinical impact of
defining whether an indeterminate mass is benign or malig-
nant is enormous. Women believed to have ovarian cancer
may require radical cytoreductive surgery by a specialist sur-
geon in gynaecological oncology [6–8]. Furthermore, women
with suspected malignancy may require transfer to a specialist
institution. Conversely, benign adnexal masses may either be
managed conservatively or undergo simple resection by a
general gynaecologist.
In addition, with the increasing use of pelvic MRI, adnexal
masses may also be identified as an incidentaloma. In our
original guidelines, we suggested that where radiologist su-
pervision of the examination was possible, an algorithmic ap-
proach could be used in order to tailor the examination, and
that in most cases an accurate diagnosis could be achieved
using one or two ‘problem-solving’ sequences in addition to
the compulsory sequences.We have reconsidered these guide-
lines in light of recent clinical and imaging developments, and
present our updated recommendations in Table 1.
New imaging techniques
Diffusion-weighted imaging (DWI)
There are now several studies confirming that DWI has a
valuable role in MR imaging of the adnexal mass [9–14].
The correct DWI technique is ensured by using a high
enough b value to suppress any high signal intensity (SI) from
freely diffusing water molecules, whilst keeping sufficient
signal-to-noise ratio to identify pathology that has restricted
water diffusion. For the female pelvis, we use the urine in the
bladder as internal reference to guarantee that the chosen high
b value is satisfactory. The urine is high in SI at b0, and
decreases as the b value increases. When the bladder SI is
fully suppressed, the optimal b value for adnexal mass char-
acterization is achieved. For gynaecological imaging charac-
terization, the optimal b value is usually 800–1000 s/mm2, but
may be increased up to 1200 or 1400 s/mm2 [10]. Once the
DWI sequence has been optimized, the lesion can then be
evaluated (Table 2 and Fig. 1).
The key points for the interpretation of DWI are as follows:
& DWI SI of water (i.e. urine in the bladder) is dark.
& The DWI SI of the mass must be compared with that on
T2WI and ADC.
& Due to considerable overlap, ADC quantification is not
useful for assessing adnexal masses [13]. In view of this,
there is—up to now—no indication to perform multi-b
value diffusion.
The presence of ‘diffusion restriction’ is evidenced by high
DWI SI on high-b-value images with corresponding low SI on
the ADCmap (Fig. 2). This differs from those tissues in which
the water molecules are not highly restricted, where the DWI
SI may be low on the high b value and high on ADC or, in the
presence of very high T2 SI lesions, the lesion may be high
and high (T2 shine-through effect).
Initial studies evaluating DWI in adnexal masses reported
high SI in mature cystic teratomas and endometriomas as well
as in malignant masses, whilst the majority of fibromas and
other benign masses had low DWI signal [9, 14]. These au-
thors rightly cautioned against using DWI as a ‘standalone’
technique, due to the overlap in common benign and malig-
nant masses [9]. DWI should not be applied in the diagnosis of
mature ovarian teratomas and endometriomas. In practice, the
great majority of these lesions can be accurately diagnosed by
simply observing their T2W features and the characteristics on
T1W and FST1W imaging.
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Rather, the added value of DWI is in assessing non-
fatty, non-haemorrhagic pelvic masses that are entirely
solid, or complex masses that are either septate cysts or
complex solid and cystic masses. Diagnostic confidence
is increased by about 15 % when DW images are added
to conventional images [12]. If the solid component of
an indeterminate adnexal mass is of low SI on T2WI,
and the entire mass displays low signal on DWI obtain-
ed with a b value of 800–1000 s/mm2, there is a very
high likelihood of benignity [11].
DWI is thus diagnostic in the majority of predomi-
nantly solid benign adnexal masses, such as ovarian
Table 1 MR imaging protocol
(2016) Patient preparation Intravenous smooth muscle relaxant
Placement of intravenous cannula
Basic MR sequences Sagittal T2W of the pelvis
Pair of T1W, T2W through the indeterminate mass
±T2W sequence in the long axis of the uterus1
Problem-solving sequences T1 ‘bright’ mass—FST1W
T2 ‘dark’ solid mass (site of origin)—oblique T2Wa
T2 ‘dark’ solid mass (nature)—DWIb
T2 solid mass—DWIb,c and CET1Wd
Cystic-solid mass—DWIb,c and CET1Wd
Note: Modifications to the previous recommendations are highlighted in grey
FST1W fat-suppressed T1-weighted, DWI diffusion-weighted imaging, DCET1W dynamic contrast- enhanced
T1-weighted
a In many cases, this oblique T2W sequence along the long axis of the uterus (‘ovarian axis’) suffices. In other
cases, a plane selected across the maximum point of contact of the mass and uterus is required to determine
whether it is ovarian or uterine in origin and to look for bridging vessels
b A solid mass which has low signal on DWI sequences with b values of ≥ 800 s/mm2 can be regarded as benign,
and CET1W imaging is unnecessary
c As T2 solid masses with intermediate to high DWI signal may be benign or malignant, additional CET1W
imaging is required
d Ideally, with DCE MRI, where a type 3 curve is highly predictive of malignancy
Table 2 How to integrate DWI in diagnostic algorithm
Diagnostic steps DWI signal at high b
value
Background Diagnosis




Very low SI Adequate high b value Can now evaluate adnexal
mass DWI













3.Compare DWI with ADC SI High SI on high b and
high SI on ADC
T2WI shine through May be seen in cysts
High SI on high b value
and low ADC
Restricted diffusion—non-specific Mature teratoma
Endometrioma
Cancer
4. ADC measurement Characterization of
lesion is not possible
based on ADC
quantification
Cancer tissue has low ADC but this is
non-specific
Overlap between benign and
malignant lesions
SI signal intensity, DWI diffusion-weighted imaging, ADC apparent diffusion coefficient, T2WI T2-weighted imaging
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fibroma or cystadenofibroma, and in most pedunculated
uterine leiomyomas. Moreover, a low T2W solid mass
with low DWI signal is highly likely to be benign,
irrespective of its pattern of contrast enhancement [12].
In these circumstances, DWI can thus replace
CET1W MRI as a confirmatory sequence for benignity
of a solid or partly solid indeterminate mass. This is of
particular relevance in pregnant women in whom con-
trast administration is contraindicated but complementa-
ry imaging to US is warranted.
Conversely, when an indeterminate adnexal mass is
solid or has a solid component with high signal on
the high-b-value DWI, it may be benign or malignant,
and CET1W MRI should be performed.
Dynamic contrast-enhanced (DCE) MR imaging
Two European centres have done pioneering work on
DCE MRI of complex adnexal lesions [15–20]. It is
well known that factors related to tumour biological
processes, such as VEGFR-2 expression and pericyte
coverage index (PCI), are related to maximum uptake
of gadolinium by the tumour [18].
Using semi-quantitative multiphase contrast-enhanced
MRI, the predominant finding by both groups was that
in adnexal masses where solid components demonstrate
a rapid rate and high level of enhancement, there is a
very high likelihood of malignancy, whereas a slow rate
and low level of enhancement is associated with a high
likelihood of a benign lesion [15–17, 20].
The analysis of dynamic contrast enhancement is
based on the comparison of the time–intensity curve of
the solid component in an adnexal mass with that of the
external myometrium which serves as internal reference.
Thus, a DCE MR sequence must be acquired in a plane
that involves the solid component of the adnexal mass
(i.e. solid papillary projections, thickened irregular septa
or solid portion) and the myometrium (Fig. 3). Either
the plane is selected by the radiologist and a 2D T1W
sequence is performed, or better, a 3D T1W sequence
Fig. 1 Characterization of
adnexal masses by combining
T2WI and DWI
Fig. 2 Ovarian carcinoma
confined to the right ovary
(arrow) displaying intermediate
SI on T2WI and restricted
diffusion characterized by high SI
on the high-b-value (b1200)
image and loss of signal on ADC
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may be acquired. Technical details for optimizing
DCE MRI (Fig. 3) are provided in the technical
appendix.
Review process
The ESUR guidelines for MRI of sonographically indetermi-
nate adnexal masses were published in 2010. In 2015, a re-
evaluation of the current practice was initiated by the expert
members. Questionnaires analysing recent clinical practice in
imaging of sonographically indeterminate adnexal masses,
notably the integration of DWI and DCE imaging, and the
type of clinical protocol were collected from 13 European
institutions and one centre in Japan. In addition, the literature
published between 1999 and 2015 was reviewed. In two
consensus meetings in 2015, a draft of the current update
was developed and discussed, and was ultimately approved
after distribution among the subcommittee members.
Updates
Indications for MRI in a sonographically indeterminate
mass
The complementary use of MRI is most beneficial in
the following clinical scenarios:
& A complex adnexal mass with equivocal malignant
features
& A large pelvic mass of indeterminate origin
Fig. 3 Technical assessment of DCE MR imaging in complex adnexal
masses. This example shows a complex right ovarian mass with a solid
component in intermediate T2W signal (a) that heterogeneously enhances
after gadolinium injection. Parametric map (maximal slope) helps to
determine the most suspicious location (hot spot) where the region of
interest should be placed to build the time–intensity curve (b). To
compare this curve with the myometrial curve, 3D T1W sequence must
be reformatted in the coronal plane to place the two ROI (solid
component and external myometrium) (c). Comparison of time–
intensity curves shows that the solid component enhances according to
a time–intensity curve type 3 (curve steeper than that of myometrium)
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& A mass adjacent to the uterus with equivocal origin
& A solid adnexal mass
Patient preparation
There are no new data. It is recommended that a smooth mus-
cle relaxant is administered intravenously or intramuscularly.
Diagnostic algorithm (Fig. 4a–c)
There are no new data regarding this, and the recommen-
dation remains that it requires basic and problem-solving im-
aging sequences. The basic imaging technique, as a minimum,
comprises the following:
& AT2W sagittal sequence of the pelvis
& A pair of T1W and T2W sequences covering the adnexal
mass and its relationship to the uterus in the same orthog-
onal (axial or coronal or oblique) plane with identical slice
thickness
The choice of which plane is used is at the discretion of the
supervising radiologist. The key is the identical position of the
pair of T1W and T2W and—if performed—DWI and DCE/
CET1W images to allow direct comparison of the entire mass.
For the 2010 guidelines [1], the decision tree divided inde-
terminate masses into three groups on the basis of their key
characteristic on the basic T1W and T2W sequences. For the
purposes of that algorithm, solid material had SI similar to
muscle on T1-weighted sequences, and cyst contents had SI
on T2W sequences similar to the urinary bladder. The three
categories of mass were as follows:
& T1 ‘bright’ masses containing T1 high SI
& T2 solid masses with predominant signal either similar to
skeletal muscle (T2 ‘dark’ solid masses) or higher than
muscle (T2 ‘intermediate’ or mixed-signal solid masses)
& Complex cystic or cystic-solid masses
T1 ‘bright’ masses (Fig. 4a)
There are no new data to guide assessment of such masses.
These masses require FST1W imaging using chemical pre-
saturation to distinguish fat from blood. The FST1W sequence
should be performed in exactly the same plane as the T1W
sequence to allow direct comparison.
Whilst haemorrhagic masses may have low signal on
T2WI, it is their T1W ‘bright’ characteristic—a reflection of
T1 shortening from extracellular methaemoglobin—that dis-
tinguishes them.
When there is concern for a solid nodule within a T1 bright
mass, additional assessment as for a complex cystic or cystic-
solid mass is required. An enhancing nodule within an endo-
metrial cyst is a finding suggesting endometriosis-associated
cancer [21]. It is recommended that the post-contrast appear-
ance is reviewed on subtracted images to improve reporting
accuracy.
As mature cystic teratomas rarely undergo malignant
change, all portions of T1 bright masses should be carefully
analysed for signs of such transformation as capsular breach
or a large heterogeneous solid component.
Caution is warranted regarding application of DWI and
DCE and overreliance on their findings for assessment of T1
bright masses. Both may yield positive findings with benign
cystic teratomas. Epidermoid components of teratomas show
diffusion restriction similar to malignant lesions, and compo-
nents of benign teratomas may also rarely rapidly enhance or
show type 3 time–intensity curves [9, 16, 22–24]. DWI of
haemorrhagic lesions may have a confusing appearance, and
offers no additional diagnostic value [10].
Fig. 4 Flow charts with revised algorithm for T1 ‘bright’ masses (a), T2 solid masses (b), and complex cystic or cystic-solid masses (c)
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Our recommendation is for no change in the evaluation of
T1 bright masses. Their fat or blood content can be determined
simply and effectively using a combination of T1W, T2Wand
FST1Wimaging. However, if these masses have solid aspects,
or if a teratoma displays a large heterogeneous solid compo-
nent, further assessment with gadolinium injection is advised.
T2 solid masses (Fig. 4b)
Well-delineated, sonographically indeterminate solid adnexal
masses raise concerns for ovarian metastases, yet in practice
almost all of these will turn out to be benign fibrous or
fibromuscular masses such as uterine leiomyomas or ovarian
fibromas [5].
The first consideration is defining their anatomic site of
origin, ovarian or uterine (Fig. 5). An ovarian fibroma is
separate from the uterus, and often only the contralateral nor-
mal ovary is seen. In a uterine leiomyoma, there may be nor-
mal uterine tissue draped around the solid mass, holding it like
a ‘claw’ (Fig. 5c and d). Uterine leiomyoma may also be
attached to the uterus by a stalk which contains the ‘bridging
vessels’ that supply it (Fig. 5e and f). The conspicuity of this
pedicle and the bridging vessels is made more obvious using
an oblique T2W sequence through the maximum point of
contact between the mass and the uterus.
From feedback through personal communication, we are
aware that in clinical practice, many radiologists feel more
comfortable confirming the diagnosis of ovarian fibroma with
CET1W imaging. Ovarian fibroma is typically slowly and
minimally enhancing, and displays a type 1 curve on DCE
MRI [14, 25]. DCE MRI may also be useful in differentiating
pedunculated subserosal leiomyomas from ovarian fibromas.
Studies have shown that enhancement of pedunculated
Fig. 5 Differentiation of ovarian
versus uterine origin. Beak sign
indicating ovarian origin in a
benign teratoma (arrows and
outlined in a and b). The most
important differential diagnosis of
a solid adnexal mass includes
uterine leiomyoma, which can be
differentiated by the claw sign
(arrow and outlined in c and d) or
in broad-based leiomyomas by
bridging vessels (arrow in e and f)
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subserosal leiomyomas parallel those of the adjacent
myometrium, whereas contrast uptake in fibromas is more
delayed [14, 25].
We now recommend DWI in T2W low-signal solid ovarian
adnexal masses, which are most likely to be an ovarian fibro-
ma or a Brenner tumour. Such a solid mass having entirely
low signal on DWI sequences with high b values can be
regarded as benign, and CET1W imaging is unnecessary.
It is our recommendation that a solid adnexal mass with T2
intermediate SI or a T2 dark mass showing other than low
DWI signal be further assessed by CET1W imaging, ideally
with DCE MRI when this is available.
Complex cystic or cystic-solid masses (Fig. 4c)
In our previous guidelines [1], we recommended CET1W
imaging for assessment of masses which raised concerns for
malignancy: some solid masses (as discussed above), solid
components within cystic masses, and nodular or irregular
thickening of internal septa or of the inner or outer aspects
of the wall of a mass. CET1W imaging remains the bench-
mark technique to look for malignant features, and is the one
most widely available [26].
However, both DWI and DCE MRI, when available, are
recommended as adjunct investigations. Persistent high signal
using b values > 800 s/mm2, with corresponding low ADC
signal indicating diffusion restriction, is found in ovarian can-
cer (Fig. 2). However, several benign lesions, including be-
nign cystic teratomas, endometrial cysts, some fibrothecomas,
degenerating leiomyomas, and Brenner tumours, may also
display such signal characteristics on DWI. Furthermore,
ADC quantification shows too much overlap to confidently
allow prediction of malignancy. Conversely, low DWI signal
using a high b value is highly predictive of a benign lesion
[11]. Recent data underscore the value of including DCE in
the routine work-up of indeterminate adnexal masses. A ret-
rospective analysis in 87 women with complex adnexal
masses demonstrated a correct change in 16–24 % of lesion
characterization when both DWI and DCE were used [12]. In
addition to peritoneal implants, the presence of a time–inten-
sity curve type 3 is the best predictor of malignancy, and this
enhancement pattern was found in no benign but in 58 % of
malignant tumours [17]. Of note, the benign sclerosing stro-
mal tumour of the ovary may display early contrast enhance-
ment; however, the centripetal enhancement pattern may sug-
gest a specific diagnosis in this extremely rare tumour among
women of childbearing age [27].
A time–intensity curve type 1, a weak and progressive
enhancement after gadolinium injection, predicts benignity
and may be especially helpful in recognizing benign stromal
tumours and cystadenofibroma that may display a high DW
signal [14, 28].
Our recommendations for complex cystic or cystic-solid
masses are that DWI and DCE MRI be used, if available, as
adjuncts to CET1W imaging.
Tubo-ovarian inflammatory disease commonly causes
complex cystic masses, with more indolent or chronic forms
typically presenting as sonographically indeterminate masses.
Complex folds and other mural abnormalities within tubal
disease may mimic neoplastic features [29]. Caution is war-
ranted in using DWI, as the high signal in these masses is
produced mainly by the liquid purulent component and not
the solid aspect. Thus, DWI must be carefully analysed in
combination with T1W and T2W images. CET1W imaging
can increase the conspicuity and improve the diagnosis of
tubal disease, and may provide some clues as to disease activ-
ity and to complications such as abscess formation.
New developments
An MRI scoring system based on standard T1WI and T2WI
appearances supplemented by DWI and DCEMRI features—
the ADNEXMR scoring system—has been proposed [17]. A
prospective multicentre study is being conducted in conjunc-
tion with the female pelvic imaging working group of the
ESUR (EURAD-MR Classification) in order to analyse the
potential impact of this model on therapeutic strategy and to
test its reproducibility. First results are expected in 2016.
18-FDG PET/CT can provide additional information to
transvaginal ultrasound (TVUS) in the differential diagnosis
of benign from malignant pelvic lesions. However, in the as-
sessment of sonographically indeterminate lesions, it is cur-
rently not recommended, due to its adherent limitations, in-
cluding physiological uptake in normal ovaries, uptake in
common benign lesions, and its potential lack of uptake in
cystic or in necrotic tumours. Furthermore, with reported sen-
sitivity of 52–58 % and specificity of 76–78 % for character-
ization of ovarian masses, it is inferior to MRI [30]. Increased
uptake of FDG in an ovarian mass in women of post-
menopausal age is indicative of a malignant tumour [30].
However, caution is warranted in benign teratomas in both
pre-and postmenopausal women [31].
The added value of the integration of PET/MRI for char-
acterization of ovarian lesions has yet to be validated [32].
Summary of new recommendations
An algorithmic MRI approach using basic and problem-
solving sequences under radiologist supervision will ensure
a specific diagnosis in the vast majority of sonographically
indeterminate adnexal masses.
We do not recommend any change in the evaluation of T1
‘bright’ masses (Fig. 4a). Their fat or blood content can be
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determined simply and effectively using a combination of
T1W, T2W and FST1W imaging. When there is concern for
a solid nodule within such a mass, it requires additional as-
sessment as for a complex cystic or cystic-solid mass.
We now recommend that DWI be applied for low T2 solid
adnexal masses (Fig. 4b). Such masses with low DWI signal
can be regarded as benign. Any solid adnexal mass which
shows intermediate or high DWI signal requires further as-
sessment by CET1W imaging, ideally with DCE MRI. This
technique may also be useful in the differentiation of uterine
from ovarian origin in such a mass.
We now recommend that for complex cystic or cystic-solid
masses, both DWI and DCE MRI are used, if available
(Fig. 4c). Otherwise, such masses are appropriately examined
using CET1W imaging.
Our recommendations are shown in new algorithms and
summarized in Table 1. These ESUR guidelines now super-
sede those from 2010.
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